EIPA
(Synonyms: 5-(N-乙基-N-异丙基)阿米洛利,L-593,754, MH 12-43, 5-(N-ethyl-N-isopropyl)-Amiloride) 目录号 : GC15893
EIPA 抑制 TRPP3 介导的 Ca2+- 激活电流，IC50 值为 10.5 μM 。
Cas No.:1154-25-2
Sample solution is provided at 25 µL, 10mM.
EIPA inhibited TRPP3-mediated Ca2+-activated currents with IC50 values of 10.5 μM [1]. TRPP3, a member of the transient receptor potential (TRP) superfamily of cation channels, is a Ca2+-activated channel permeable to Ca2+, Na+, and K+ [1].EIPA (5-(N-ethyl-N-isopropyl)-amiloride) is a commonly used amiloride derivative modified similarly to MPA, and its Ki for NHE1, NHE2, and NHE3 are 0.3, 1.8, and 67 μM, respectively[2,3]
EIPA suppressed proliferation of MKN28 cells through up-regulation of p21 expression via reduction of [Cl- ] c as a result from DIDS-sensitive Cl- /HCO3- exchanger-mediated compensation for keeping pHc normal under an NHE-inhibited condition [4].
EIPA preischemic treatment overcame the I/R-induced renal dysfunction. Histologic examination of the kidney of vehicle-treated ARF mice revealed severe lesions, and these lesions were significantly suppressed by the preischemic treatment with EIPA. In addition, EIPA suppressed the increment of renal ET-1 content after reperfusion [5]. EIPA at doses of 3 and 9 mg/kg per day inhibited tumor growth of HepG2 modle mice significantly compared with the control [6].
References:
[1]. Dai XQ, Ramji A, Liu Y, Li Q, Karpinski E, Chen XZ (2007) Inhibition of TRPP3 channel by amiloride and analogs. Mol Pharmacol 72:1576-1585
[2]. Guffey, S.C.; Fliegel, L.; Goss, G.G. Cloning and characterization Na+/H+ Exchanger isoforms, NHE2 and, NHE3 from the gill Pacific dogfish, Squalus suckleyi. Comp. Biochem. Physiol. Part B Biochem. Mol. Biol. 2015, 188, 46-53.
[3]. Masereel, B. An overview inhibitors Na+/H+ exchanger. Eur. J. Med. Chem. 2003, 38, 547-554.
[4]. Hosogi SMH, Nakajima K, Ashihara E, Niisato N, Kusuzaki K, Marunaka Y: An inhibitor of Na(+)/H(+) exchanger (NHE), ethyl-isopropyl amiloride (EIPA), diminishes proliferation of MKN28 human gastric cancer cells by decreasing the cytosolic Cl(-) concentration via DIDS-sensitive pathways. Cell Physiol Biochem. 2012, 30: 1241-1253. 10.1159/000343315.
[5]. Yamashita J, Ohkita M, Takaoka M, Kaneshiro Y, Matsuo T,Kaneko K, Matsumura Y.Role of Na+/H+ exchanger in the pathogen-esis of ischemic acute renal failure in mice.J Cardiovasc Pharmacol49:154 -160, 2007.
[6]. X. Yang, D. Wang, W. Dong, Z. Song, K. Dou.Expression and modulation of Na+/H+ exchanger 1 gene in hepatocellular carcinoma: a potential therapeutic target. J. Gastroenterol. Hepatol., 26 (2) (2011), pp. 364-370
EIPA 抑制 TRPP3 介导的 Ca2+- 激活电流，IC50 值为 10.5 μM [1]。 TRPP3 是阳离子通道瞬时受体电位 (TRP) 超家族的成员，是 Ca2+- 激活通道，可渗透 Ca2+、Na+ 和 K+ [1].EIPA (5-(N-ethyl-N -isopropyl)-amiloride)是一种常用的类似MPA修饰的阿米洛利衍生物，其对NHE1、NHE2和NHE3的Ki值分别为0.3、1.8和67 μM[2,3] /p>\n
EIPA 通过减少 [Cl-] c 上调 p21 表达来抑制 MKN28 细胞的增殖，这是由于 DIDS 敏感的 Cl- /HCO3- 交换剂介导的补偿，以在 NHE 抑制条件下保持 pHc 正常[4].
EIPA 缺血前治疗克服了 I/R 引起的肾功能障碍。载体治疗的 ARF 小鼠肾脏的组织学检查显示严重病变，并且这些病变被 EIPA 的缺血前治疗显着抑制。此外，EIPA抑制再灌注后肾脏ET-1含量的增加[5]。与对照组相比，每天 3 和 9 mg/kg 剂量的 EIPA 显着抑制 HepG2 模型小鼠的肿瘤生长[6]。
EIPA 通过减少 [Cl-] c 上调 p21 表达来抑制 MKN28 细胞的增殖，这是由于 DIDS 敏感的 Cl- /HCO3- 交换剂介导的补偿，以在 NHE 抑制条件下保持 pHc 正常[4].
EIPA 缺血前治疗克服了 I/R 引起的肾功能障碍。载体治疗的 ARF 小鼠肾脏的组织学检查显示严重病变，并且这些病变被 EIPA 的缺血前治疗显着抑制。此外，EIPA抑制再灌注后肾脏ET-1含量的增加[5]。与对照组相比，每天 3 和 9 mg/kg 剂量的 EIPA 显着抑制 HepG2 模型小鼠的肿瘤生长[6]。
| Cell experiment [1]: | |
|
Cell lines |
MCF-7 cells |
|
Preparation Method |
Cells were seeded in 6-well plates for 24 h prior to 48 h-treatment with EIPA (10 µM), Akti (1 µM), U0126 (10 µM) or a combination thereof. |
|
Reaction Conditions |
10µM for 48 hours |
|
Applications |
MCF-7 cells were subjected to treatment with EIPA with and without ERK and Akt inhibitors. ERK, but not Akt, activity was increased upon EIPA treatment, and both kinases were effectively inhibited by their inhibitors, U0126 and Akti, respectively. Strikingly, ERK inhibition strongly potentiated EIPA-induced CHOP upregulation and PARP cleavage. |
| Animal experiment [2]: | |
|
Animal models |
Female homozygous BALB/c Nu/Nu nude mice were injected subcutaneously (s.c.) in both flanks at 7 weeks of age with 106 parental and IKKαδ MIA PaCa-2 cells or 1334 and 1444 cells mixed at a 1:1 dilution with BD Matrigel (BD Biosciences) in a total volume of 100 µl. |
|
Preparation Method |
Mice were treated with vehicle (DMSO in PBS), EIPA (7.5 mg/kg), MRT68921 (10 mg/kg) or MRT68921+EIPA for 15 days when tumors attained an average volume of 50-100 mm3. |
|
Dosage form |
s.c., 7.5 mg/kg/d for 7 days |
|
Applications |
One month of EIPA treatment, initiated at age 1 month, markedly reduced pancreatic weight (a tumor burden surrogate), inhibited acinar-to-ductal metaplasia (ADM) and advanced PanIN formation, and preserved the normal pancreatic parenchyma in KrasG12D;IkkαδPEC mice, while decreasing MP. |
|
References: [1]: M.G. Rolver, L.O. Elingaard-Larsen, A.P. Andersen, L. Counillon, S.F. Pedersen. Pyrazine ring-based Na+/H+ exchanger (NHE) inhibitors potently inhibit cancer cell growth in 3D culture, independent of NHE1.Sci. Rep., 10 (2020), p. 5800 |
|
| Cas No. | 1154-25-2 | SDF | |
| 别名 | 5-(N-乙基-N-异丙基)阿米洛利,L-593,754, MH 12-43, 5-(N-ethyl-N-isopropyl)-Amiloride | ||
| 化学名 | 3-amino-6-chloro-N-(diaminomethylene)-5-(ethyl(isopropyl)amino)pyrazine-2-carboxamide | ||
| Canonical SMILES | ClC1=NC(C(/N=C(N)\N)=O)=C(N)N=C1N(CC)C(C)C | ||
| 分子式 | C11H18ClN7O | 分子量 | 299.76 |
| 溶解度 | 14mg/mL in DMSO, 20mg/mL in DMF, 2mg/mL in Ethanol | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.336 mL | 16.68 mL | 33.36 mL |
| 5 mM | 0.6672 mL | 3.336 mL | 6.672 mL |
| 10 mM | 0.3336 mL | 1.668 mL | 3.336 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet